0001209191-21-010882.txt : 20210216
0001209191-21-010882.hdr.sgml : 20210216
20210216174905
ACCESSION NUMBER: 0001209191-21-010882
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210211
FILED AS OF DATE: 20210216
DATE AS OF CHANGE: 20210216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ordonez Claudia
CENTRAL INDEX KEY: 0001808290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 21641393
MAIL ADDRESS:
STREET 1: C/O KEROS THERAPEUTICS, INC.
STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-11
0
0001664710
Keros Therapeutics, Inc.
KROS
0001808290
Ordonez Claudia
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
0
1
0
0
Chief Medical Officer
Common Stock
2021-02-11
4
M
0
1000
0.48
A
1000
D
Common Stock
2021-02-11
4
S
0
175
63.10
D
825
D
Common Stock
2021-02-11
4
S
0
312
64.17
D
513
D
Common Stock
2021-02-11
4
S
0
216
65.35
D
297
D
Common Stock
2021-02-11
4
S
0
295
66.19
D
2
D
Common Stock
2021-02-11
4
S
0
2
68.05
D
0
D
Employee Stock Option (right to buy)
0.48
2021-02-11
4
M
0
1000
0.00
D
2029-09-18
Common Stock
1000
102211
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to
$63.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in
footnotes (2), (3), (4) and (5).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.775 to
$64.535 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.855 to
$65.73 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to
$66.69 inclusive.
One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
/s/ Keith Regnante, Attorney-in-Fact
2021-02-16